MRT-3 free antigen testing ends on June 30 | Inquirer News

MRT-3 free antigen testing ends on June 30

By: - Reporter / @zacariansINQ
/ 07:02 PM June 23, 2022

New train coaches of MRT-3

New train coaches of MRT-3

MANILA, Philippines — The Department of Transportation’s (DOTr) free antigen testing for COVID-19 in Metro Rail Transit Line 3 (MRT-3) will end on June 30, the railway management said Thursday.

“Huling araw ng pamamahagi ng LIBRENG ANTIGEN TESTING ng pamunuan ng MRT-3 para sa mga boluntaryong pasahero nito sa ika-30 ng Hunyo, 2022,” said the management of MRT-3 in an advisory on Thursday.

Article continues after this advertisement

(Last day of distribution of free antigen testing by the MRT-3 management for its volunteer passengers on June 30, 2022.)

FEATURED STORIES

The management said commuters could avail themselves of free antigen testing in North Avenue stations, Shaw Boulevard stations from 7 a.m. to 8 a.m., and Cubao and Shaw stations from 4:00 p.m. to 5:00 p.m.

It can be recalled that the DOTr started its free random antigen screenings for MRT-3 from January 11 to 31, before resuming on Feb. 2.

Article continues after this advertisement

“Simula ika-28 ng Enero, 2022, walang anumang kaso ng nagpositibo sa COVID-19 ang naitala sa antigen testing para sa mga pasahero,” the MRT-3 management said.

Article continues after this advertisement

(Since Jan. 28, no cases of COVID-19 positive have been recorded in antigen testing for passengers.)

Meanwhile, the MRT-3 management also announced that the railway system’s free ride program will continue until June 30.

RELATED STORIES:

Free rides at Edsa Carousel will continue until July 31

Over 71 million have used free transport service since April

JMS/abc
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: antigen test, DoTr, free MRT-3 rides

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.